On-Demand CME Videos

Plaque Psoriasis: Itching for New Topical Options: Online CME Activity


This activity was recorded at the 2022 Fall Clinical Dermatology Conference on October 22, 2022.

CME Seminar-in-Depth:

Plaque Psoriasis: Itching for New Topical Options 

This activity is supported by an educational grant from Arcutis. 


In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

November 15, 2022

Expiration Date:

November 15, 2024

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Overview of key data for emerging topical therapies to manage plaque psoriasis

  • Describe how to individualize care with emerging topical therapies to optimize patient outcomes

  • Compare between the various topical therapies for the management of plaque psoriasis

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
April Armstrong, MD, MPH

Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

Neal Bhatia, MD

Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers


In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

April W. Armstrong, MD, MPH

Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen 

Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel 

Neal D. Bhatia, MD

Advisory Board/Consultant: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN

Grant/Research Support: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN

Speaker's Bureau: Almirall, Biofrontera, Ferndale, Galderma, ISDIN, J & J, La Roche-Posay, Ortho, and SUN

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.


The leading platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved